Document Type : Original Article



CONTEXT: India experienced pandemic phase of H1N1 in May 2009 to December 2010. The
postpandemic phase went on from January 2011 to December 2014. As per the WHO, all countries
should immunize their health‑care workers as a first priority to protect the essential health infrastructure.
AIMS: The aim of the study is to assess the level of awareness and acceptance of influenza vaccine
among physicians and also the perception of physicians regarding H1N1 infection. This study also
examined time of vaccine administration in relation with efficacy concerns based on literature.
SETTINGS AND DESIGN: A vaccination campaign was conducted for all health‑care workers of
Seth GSMC and KEM Hospital, Mumbai, in the month of July 2017 based on which a cross‑sectional
observational study was conducted among the physicians of the same institute.
METHODS: After ethical clearance, a prevalidated pretested survey based on a pilot survey of 20
physicians was distributed among physicians, which was based on the awareness and acceptance of
H1N1 vaccination among physicians and perception of H1N1 infection. Effective sample size was 272.
STATISTICAL ANALYSIS USED: Descriptive statistics and Chi‑square test were generated for
the survey responses. All the continuous variables were reported as mean, median, and range.
Categorical variables were reported as tables and pie charts. P < 0.05 was taken as significant. Data
analysis was done with SPSS version 21.
RESULTS: The overall vaccine compliance was 29.8%. This study has found that area of work,
deficiency in knowledge about adverse effect of vaccine, misconceptions regarding vaccine, and
concerns about efficacy and duration of vaccine are the important factors which lead to decreased
vaccine compliance. Furthermore, it is found during the study that timing of vaccination was not given
due importance as considering the epidemiological pattern.
CONCLUSIONS: More emphasis should be given to education sessions and counseling of physicians
regarding H1N1 vaccination and oseltamivir therapy. At administrative level, more focus should be
given on timing of vaccination and other logistics. Vaccine campaigns should be conducted ideally
1 month before expected rise in cases. Quadrivalent vaccine would be more appropriate over trivalent
based on epidemiology of infection in India.


  1. The Hindu.(2018).In the grip of a fever.[online] Available at: https://‑tech/health/in‑the‑grip‑of‑a‑fever/
    article25017325.ece [Accessed 28 Sep. 2018].
    2. World Health Organization. WHO Recommendations on
    Pandemic (H1N1) 2009 Vaccines. World Health Organization;
    3. Torun SD, Torun F. Vaccination against pandemic influenza
    A/H1N1 among healthcare workers and reasons for refusing
    vaccination in Istanbul in last pandemic alert phase. Vaccine
    4. Center for Disease Control. What is Guillain‑Barré
    syndrome (GBS)? What causes GBS? Center for Disease Control;
    5. (2017). Weekly epidemiological record. [online]
    Available at:
    handle/10665/255611/WER9222.pdf; jsessionid=FAB745EC928
    F5B1B48B07AAA869DF0C2?sequence=1 [Accessed 20 Sep. 2018].
  2. 6. Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza
    vaccination of health care workers in hospitals – A review of
    studies on attitudes and predictors. Vaccine 2009;27:3935‑44.
    7. Hidiroglu S, Ay P, Topuzoglu A, Kalafat C, Karavus M. Resistance
    to vaccination: The attitudes and practices of primary healthcare
    workers confronting the H1N1 pandemic. Vaccine 2010;28:8120‑4.
    8. Seale H, Kaur R, Wang Q, Yang P, Zhang Y, Wang X, et al.
    Acceptance of a vaccine against pandemic influenza A (H1N1)
    virus amongst healthcare workers in Beijing, China. Vaccine
    9. Najimi A, Golshiri P. Knowledge, beliefs and preventive behaviors
    regarding influenza A in students: A test of the health belief
    model. J Educ Health Promot 2013;2:23.
    10. Sundaram N, Purohit V, Schaetti C, Kudale A, Joseph S,
    Weiss MG, et al. Community awareness, use and preference
    for pandemic influenza vaccines in Pune, India. Hum Vaccin
    Immunother 2015;11:2376‑88.
    11. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM,
    et al. Antiviral agents for the treatment and chemoprophylaxis
    of influenza – Recommendations of the advisory committee
    on immunization practices (ACIP). MMWR Recomm Rep
    12. Center for Disease Control. Misconceptions about Seasonal Flu
    and Flu Vaccines. Seas Influ. Center for Disease Control; 2013.
    p. 18‑21.
    13. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next
    generation influenza vaccines: Formulation and production
    strategies. Eur J Pharm Biopharm 2015;94:251‑63.
    14. Swine Flu Catching them Young. The Hindu; 2017Available
    swine‑flu‑catching‑them‑young/article19571938.ece. [Last
    accessed on 2017 Aug 28].
    15. WHO. Vaccination Timing; 2018. p. 14‑5. Available from: http://
    en/. [Last accessed on 2018 Mar 13].
    16. Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M,
    et al. Quadrivalent influenza vaccine: A new opportunity to reduce
    the influenza burden. J Prev Med Hyg 2016;57:E28‑33.
    17. Brogan AJ, Talbird SE, Davis AE, Thommes EW, Meier G.
    Cost‑effectiveness of seasonal quadrivalent versus trivalent
    influenza vaccination in the United States: Adynamic transmission
    modeling approach. Hum Vaccin Immunother 2017;13:533‑42.
    18. Yang MC, Tan EC, Su JJ. Cost‑effectiveness analysis of
    quadrivalent versus trivalent influenza vaccine in Taiwan:
    A lifetime multi‑cohort model. Hum Vaccin Immunother
    19. You JH, Ming WK, Chan PK. Cost‑effectiveness of quadrivalent
    influenza vaccine in Hong Kong – A decision analysis. Hum
    Vaccin Immunother 2015;11:564‑71.
    20. ThorringtonD, van Leeuwen E, RamsayM, PebodyR, BaguelinM.
    Cost‑effectiveness analysis of quadrivalent seasonal influenza
    vaccines in England. BMC Med 2017;15:166.
    21. García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J,
    Morano Larragueta R, et al. Cost‑effectiveness analysis of
    quadrivalent influenza vaccine in Spain. Hum Vaccin Immunother